{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:30:07Z","timestamp":1792153807031,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xops.2025.101003","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T11:52:41Z","timestamp":1763034761000},"page":"101003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7861-1563","authenticated-orcid":false,"given":"Stephen J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna S.","family":"Gangaputra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al Hussein Al Awamlh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"McNeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.101003_bib1","series-title":"IDF Diabetes Atlas","year":"2021"},{"key":"10.1016\/j.xops.2025.101003_bib2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xops.2025.101003_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154411","article-title":"The accuracy of diagnostic methods for diabetic retinopathy: a systematic review and meta-analysis","volume":"11","author":"Martinez-Vizcaino","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2025.101003_bib4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/db07-1618","article-title":"Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited","volume":"57","author":"Lachin","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2025.101003_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00281-008-0111-x","article-title":"Immunological mechanisms in the pathogenesis of diabetic retinopathy","volume":"30","author":"Adamis","year":"2008","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.xops.2025.101003_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.101003_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2006.09.016","article-title":"Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells","volume":"193","author":"Piga","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.xops.2025.101003_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/ATVBAHA.110.217901","article-title":"Protein kinase C upregulates intercellular adhesion molecule-1 and leukocyte-endothelium interactions in hyperglycemia via activation of endothelial expressed calpain","volume":"31","author":"Smolock","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.xops.2025.101003_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1464-5491.2007.02217.x","article-title":"Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes","volume":"24","author":"Spijkerman","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.xops.2025.101003_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583687","article-title":"The role of inflammation in diabetic retinopathy","volume":"11","author":"Forrester","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xops.2025.101003_bib11","article-title":"Nonsteroidal anti-inflammatory drugs for retinal disease","volume":"2013","author":"Schoenberger","year":"2013","journal-title":"Int J Inflam"},{"key":"10.1016\/j.xops.2025.101003_bib12","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.2337\/diabetes.54.12.3418","article-title":"Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects","volume":"54","author":"Sun","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2025.101003_bib13","first-page":"757","article-title":"Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101003_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diab.38.4.491","article-title":"Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial","volume":"38","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2025.101003_bib15","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1185\/030079907X218770","article-title":"The effect of long-term treatment with sulindac on the progression of diabetic retinopathy","volume":"23","author":"Hattori","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.xops.2025.101003_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/IAE.0b013e3181bcf1a0","article-title":"Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema","volume":"30","author":"Chew","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.101003_bib17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/archophthalmol.2009.308","article-title":"Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal\/grid photocoagulation","volume":"127","author":"Bressler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.101003_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ophtha.2016.11.034","article-title":"Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy","volume":"124","author":"Wykoff","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101003_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ophtha.2021.07.009","article-title":"Intravitreal pharmacotherapies for diabetic macular edema: a report by the American Academy of Ophthalmology","volume":"129","author":"Ehlers","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101003_bib20","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1167\/iovs.12-10410","article-title":"Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines","volume":"53","author":"Schoenberger","year":"2012","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101003_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamaophthalmol.2013.5692","article-title":"Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%","volume":"132","author":"Schoenberger","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.101003_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaophthalmol.2013.6203","article-title":"Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy","volume":"132","author":"Schoenberger","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.101003_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.26502\/fjor.2644-002400101","article-title":"Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy (INSPIRE): study design and baseline characteristics","volume":"8","author":"Gangaputra","year":"2025","journal-title":"J Ophthalmol Res"},{"key":"10.1016\/j.xops.2025.101003_bib24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"issue":"5 Suppl","key":"10.1016\/j.xops.2025.101003_bib25","first-page":"823","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101003_bib26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/archopht.119.4.547","article-title":"How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy","volume":"119","author":"Klein","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.101003_bib27","first-page":"1005","article-title":"Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy","volume":"22","author":"Chen","year":"2016","journal-title":"Mol Vis"},{"key":"10.1016\/j.xops.2025.101003_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/archophthalmol.2007.65","article-title":"Microglial activation in human diabetic retinopathy","volume":"126","author":"Zeng","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.101003_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564077","article-title":"Microglia and inflammatory responses in diabetic retinopathy","volume":"11","author":"Kinuthia","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xops.2025.101003_bib30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/02713683.2019.1570274","article-title":"Interleukin-6 and diabetic retinopathy: a systematic review and meta-analysis","volume":"44","author":"Yao","year":"2019","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.xops.2025.101003_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956795","article-title":"Interleukin-6 inhibition in the treatment of autoinflammatory diseases","volume":"13","author":"Koga","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xops.2025.101003_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jlb.56.5.559","article-title":"Essential involvement of interleukin-8 (IL-8) in acute inflammation","volume":"56","author":"Harada","year":"1994","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.xops.2025.101003_bib33","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.4103\/1673-5374.339500","article-title":"Interleukin-4 promotes microglial polarization toward a neuroprotective phenotype after retinal ischemia\/reperfusion injury","volume":"17","author":"Chen","year":"2022","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.xops.2025.101003_bib34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41419-022-05433-0","article-title":"IL-4 induces reparative phenotype of RPE cells and protects against retinal neurodegeneration via Nrf2 activation","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.xops.2025.101003_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0161-6420(95)30973-6","article-title":"Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial","volume":"102","year":"1995","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452500301X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452500301X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:37:30Z","timestamp":1773938250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266691452500301X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S266691452500301X"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.101003","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.101003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"101003"}}